Company:  PROTALIX BIOTHERAPEUTICS, ... (PLX)
Form Type:  10-Q
Filing Date:  8/3/2012 
CIK:  0001006281 
Address:  2 SNUNIT ST
SCIENCE PARK, POB 455
 
City, State, Zip:  CARMIEL,  20100 
Telephone:  972-4-988-9488 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.13  
Change: 
-0.04 (-0.96%)  
Trade Time: 
04:01 PM EST  
Market Cap: 
$386.49M
Description of Business
We are a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx� protein expression system, or ProCellEx. Using our ProCellEx system, we are developing a pipeline of proprietary, biobetter and biosimilar versions of recombinant therapeutic proteins, based on our plant cell-based expression technology, that primarily target large, established pharmaceutical markets and that rely upon known biological mechanisms of action. Our initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. We believe ProCellEx will enable us to develop proprietary recombinant proteins that are therapeutically equivalent or superior to existing recombinant proteins currently marketed for the same indications.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures ...
    PART II - OTHER INFORMATION
      Item 1. Legal Proceedings ...
      Item 1A. Risk Factors ...
      Item 2. Unregistered Sales of Equity Securities and Use of ...
      Item 3. Defaults Upon Senior Securities ...
      Item 4. Mine Safety Disclosures ...
      Item 5. Other Information ...
      Item 6. Exhibits ...
    Signatures ...
    PART I - FINANCIAL INFORMATION
      Item 1. Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
          NOTE 4 - SUBSEQUENT EVENTS
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 31.2
    CERTIFICATION
  EXHIBIT 32.1
    CERTIFICATION
  EXHIBIT 32.2
    CERTIFICATION
BROKERAGE PARTNERS